Business
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM)
About this update from Pmv Pharmaceuticals, Inc.
[{"type":"image","alt":"PMV Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"PMV Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/877923264781c86b6a593db1aa3fc22b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H9FAajfuuaIXn5mRAIFvSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/877923264781c86b6a593db1aa3fc22b","width":282,"height":81}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM). The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients.","length":599,"tagName":"p"},{"type":"text","content":"The study published in NEJM entitled, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” highlighted the antitumor activity of rezatapopt in heavily pretreated patients across multiple solid tumor-types establishing proof-of-concept for p53 reactivation. All responding patients had a TP53 Y220C mutation and were KRAS wild-type. The manuscript can be accessed here.","length":400,"tagName":"p"},{"type":"text","content":"In the Phase 1 portion of the PYNNACLE clinical trial, 77 heavily pretreated patients with advanced solid tumors harboring a TP53 Y220C mutation received oral rezatapopt across dose-escalation cohorts to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), characterize safety, pharmacokinetics, and biomarker effects. Rezatapopt was generally well tolerated; dose-limiting toxicities were infrequent, supporting selection of the RP2D. Objective responses were observed across multiple tumor types. Clinical activity and biomarker data were consistent with selective binding to the Y220C pocket and restoration of wild-type p53 tumor suppressor function.","length":675,"tagName":"p"},{"type":"text"...